These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35350741)

  • 1. Building in-house PBPK modelling tools for oral drug administration from literature information.
    Grandoni S; Cesari N; Brogin G; Puccini P; Magni P
    ADMET DMPK; 2019; 7(1):4-21. PubMed ID: 35350741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.
    Margolskee A; Darwich AS; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Laplanche L; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():610-625. PubMed ID: 27816631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
    Bouzom F; Ball K; Perdaems N; Walther B
    Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data.
    Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS
    Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling and PBPK simulation in drug discovery.
    Jones HM; Gardner IB; Watson KJ
    AAPS J; 2009 Mar; 11(1):155-66. PubMed ID: 19280352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel strategy for physiologically based predictions of human pharmacokinetics.
    Jones HM; Parrott N; Jorga K; Lavé T
    Clin Pharmacokinet; 2006; 45(5):511-42. PubMed ID: 16640456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach.
    Malmborg J; Ploeger BA
    J Pharmacol Toxicol Methods; 2013; 67(3):203-13. PubMed ID: 23280406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
    Khalil F; Läer S
    AAPS J; 2014 Mar; 16(2):226-39. PubMed ID: 24399240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance.
    Horiuchi K; Ohnishi S; Matsuzaki T; Funaki S; Watanabe A; Mizutare T; Matsumoto S; Nezasa KI; Hasegawa H
    J Pharm Sci; 2018 May; 107(5):1443-1453. PubMed ID: 29331382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of PBPK modelling in drug discovery and development at Pfizer.
    Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
    Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.